Prenzler Nils K, Salcher Rolf, Lenarz Thomas, Gaertner Lutz, Lesinski-Schiedat Anke, Warnecke Athanasia
Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hanover, Germany.
Cluster of Excellence "Hearing 4 All" (DFG Exc. 2177), Hannover Medical School, Hanover, Germany.
Front Neurosci. 2023 Jul 26;17:1202429. doi: 10.3389/fnins.2023.1202429. eCollection 2023.
In a previous study, an inner ear catheter was used to deliver low- and high-dose steroids into the cochlea prior to cochlear implant electrode insertion. With this approach, more apical regions of the cochlea could be reached and a reduction of electrode impedances in the short term was achieved in cochlear implant recipients. Whether intracochlear application of drugs via the catheter is a safe method also for patients with residual hearing has not been investigated hitherto. The aim of the present study was therefore to investigate the effect of intracochlear triamcinolone application in cochlear implant recipients with residual hearing.
Patients with residual hearing were administered triamcinolone-acetonide (4 mg/ml; = 10) via an inner ear catheter just prior to insertion of a MED-EL FLEX28 electrode. Impedances were measured at defined time points (intra-operatively, post-operatively and at first fitting) and retrospectively compared with a control group (no steroid application) and low- and high-dose group. Hearing thresholds were measured preoperatively, 3 days after surgery and at first fitting by pure tone audiometry. Pre- to postoperative hearing loss was determined at first fitting and compared to results from a previous study.
The median hearing loss after implantation (125-1,500 Hz) was 20.6 dB. Four patients (40%) showed a median hearing loss of less than 15 dB, three patients (30%) between 15 and 30 dB and three patients (30%) more than 30 dB. The median hearing loss was similar to the results obtained from our previous study showing a median hearing loss of 24 dB when using FLEX28 electrode arrays.
No difference in residual hearing loss was found when comparing application of triamcinolone-acetonide using an inner ear catheter prior to the insertion of a FLEX28 electrode array to the use of the FLEX28 electrode array without the catheter. Thus, we conclude that application of drugs to the cochlea with an inner ear catheter could be a feasible approach in patients with residual hearing.
在之前的一项研究中,在植入人工耳蜗电极之前,使用内耳导管将低剂量和高剂量的类固醇药物输送到耳蜗中。通过这种方法,可以到达耳蜗的更多顶端区域,并且人工耳蜗植入受者在短期内实现了电极阻抗的降低。迄今为止,通过导管在耳蜗内应用药物对于仍有残余听力的患者是否也是一种安全的方法尚未得到研究。因此,本研究的目的是调查在仍有残余听力的人工耳蜗植入受者中,在耳蜗内应用曲安奈德的效果。
在插入MED-EL FLEX28电极之前,通过内耳导管为仍有残余听力的患者施用曲安奈德-丙酮化物(4毫克/毫升;n = 10)。在规定的时间点(术中、术后和首次调试时)测量阻抗,并与对照组(未施用类固醇)以及低剂量和高剂量组进行回顾性比较。通过纯音听力测定法在术前、术后3天和首次调试时测量听力阈值。在首次调试时确定术前至术后的听力损失,并与之前一项研究的结果进行比较。
植入后的平均听力损失(125 - 1500赫兹)为20.6分贝。4名患者(40%)的平均听力损失小于15分贝,3名患者(30%)在15至30分贝之间,3名患者(30%)超过30分贝。平均听力损失与我们之前的研究结果相似,使用FLEX28电极阵列时平均听力损失为24分贝。
在插入FLEX28电极阵列之前,使用内耳导管施用曲安奈德-丙酮化物与不使用导管而使用FLEX28电极阵列相比,在残余听力损失方面未发现差异。因此,我们得出结论,使用内耳导管向耳蜗施用药物对于仍有残余听力的患者可能是一种可行的方法。